AstraZeneca touts a fresh cut of Farxiga data targeting diabetes patients with chronic kidney disease
As the SGLT2 race for diabetes turns hot, AstraZeneca — one of the earliest players in the field — has laid out data demonstrating its drug’s benefits …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
